Tom Brockbank Consultant Joined GPI in May 2018 This weeks Employee Spotlight focuses on Tom Brockbank. Tom is a part of the core consultancy team based in our London office, whom help to guide our clients consulting requests on a daily basis….
Alexandrosz Czira Manager Joined GPI in September 2018 Global Pricing Innovations wouldn’t be the smart & fun company it is without our talented staff. So we decided to give you a little insight into some of the amazing employees who help…
We are full steam ahead here at Global Pricing Innovations, with a fantastic productive start to 2019! Due to our continued growth & expansion, we are still actively recruiting for the below list of roles: Pricing and Market Access Consultants Director – Web…
By Tom Brockbank, Henrike Granzow and Alexandrosz Czira, GPI Current treatment options and target indications Malignant melanoma is the most lethal form of skin cancer1. In the UK approximately 15,400 new cases occur per year, and since the early 1990’s the incidence…
Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape…
Biosimilar launches of antineoplastic monoclonal antibodies represent a milestone in oncological care but also a new chapter in the application of biosimilars; introducing more prescribers, payers and stakeholders to the biological copies. Rituximab biosimilars came to the European market in 2017, while trastuzumab…
GPI LEAP creates a clear vision for the most ambitious talent by inspiring individuals from diverse backgrounds to come together, grow and succeed in an innovative and dynamic team. We are passionate about growing and developing a world-class, high-performing team of experts through…
Legal questions around the “Mischpreis” pricing approach are still hanging over sickness funds and manufacturers in Germany. The current price setting methodology as part of AMNOG negotiations take average weighted prices and considers the value and price potential across all indications and patient…
One of the advantages of working in a global consultancy and technology solutions firm such as Global Pricing Innovations (GPI), which specializes in pharmaceutical pricing, is the wide exposure one receives to the many different challenges across disease areas, companies, and geographies. This…
Global Pricing Innovations are hiring! We are looking for pharmacists and project managers to join our expanding London based team. Please contact us for further information or email your resume to careers@globalpricing.com.
Partners4Access (P4A), the orphan drug specialists, and Global Pricing Innovations (GPI), the pricing experts, are moving to larger premises in central London to account for expansion and growth. Aligned to their innovative thinking and approach with their pharmaceutical clients, the new premises are…
Global Pricing Innovations (GPI) has further strengthened its technology division with the addition of Mikhael Aktsyzniy Mikhael joins GPI from Accenture as Head of Technology and Development to continue GPI’s success providing powerful pharma pricing intelligence based business services to valued clients across…
By Pati Ladron, Global Pricing Innovations In the face of restricted budgets, payers worldwide are increasingly using Health Technology Assessments (HTAs) as a way of managing healthcare budgets by providing access to therapies that demonstrate robust clinical and economic effectiveness. HTAs are a…
GPI are hiring! We are looking for innovative, team-orientated individuals to fill a number of open positions. Pricing Analyst – Data analyst from a pharma/health economics background PMA Consultant – Experienced consultant with solid background in project management and pricing strategies and/or modelling…
Canada’s plan to revise reference basket In a bid to reduce medicine prices in Canada, the Canadian Minister of Health announced the revision of the reference basket for international reference pricing (IRP). Medicines prices in Canada are regulated by the federal government, through…
With the largest population in the Middle East and North Africa region, Egypt has attracted a strong presence from multinational pharmaceutical companies. However, current turmoil over drug shortages and drug price hikes underscores the volatility of a market characterised by high out-of-pocket spending….
By Preeti Patel and Sophie Schmitz on Oct 3, 2016 We analyze recent changes in Germany’s pharmaceutical legislation & implications for the industry. Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial…
Pati Ladron – Client Solutions Lead at GPI Published 6th July 2016 …
Brexit: in or out? If you have lived in the UK for the past year, or anywhere else in the world for that matter, you are probably very familiar with the term. As one of the biggest political decisions of the 21st century,…
The PR & MA environment is evolving at a fast pace and securing access at the right price remains challenging. Successful adaptation is the key to effectively succeed in this ever-changing world, however, most companies find adapting to change difficult. In this…
How data-driven insights can be used to effectively drive decision making within price and access. How great would it be to be able to predict the future? Successful decision making ultimately depends on our ability to predict the future outcomes of today’s…
